To investigate the efficacy of the treatment in patients with acute cerebral infarction with Yindanxinnaootong capsule, and the influence on serum hs-CRP, TNF-α and IL-6. Methods:Totally 70 cases of acute cerebral infarction were randomly collected from July-2016 to July 2015, and were randomly divided into a study group and a control group with 35 cases in each. Two groups of patients were given conventional treatment, and also Aspirin Enteric-coated Tablets orally, 100 mg each time, once per day; piracetam orally, 0.8 g each time, 3 times per day; edaravone injection, 30 mg each time, twice per day.Besides, the study group was combined with Yindanxinnaotong capsule, oral administration, 3 tablets, 3 times per day. Two groups of patients were treated for 2 weeks. The serum levels of hs-CRP, TNF-α and IL-6 were detected in two groups before treatment, after 1 week of treatment and 2 weeks, and the MESS score and Barthel index score were evaluated. Results:1) The Barthel index and MESS score of the two groups were significantly improved (P<0.05), but the improvement of the study group was significantly better than that of the control group. 2) The serum levels of hs-CRP, TNF-α and IL-6 were significantly decreased (P<0.05) in 1 and 2 weeks of treatment, but the 3 indexes in the study group were significantly lower than those of the control group (P<0.05). 3) The total effective rate of the study group at 1 week was 68.6% and 85.7% at 2 weeks, which was both significantly higher than that of the control group (54.3% and 74.3%) (P<0.05). There were no serious adverse drug events in the two groups during the treatment. Conclusion:Yindanxinnaotong capsule inhibits the inflammatory injury of acute cerebral infarction, and can effectively improve the patient’s neurological symptoms and function of pursuing daily activity.